Abstract

PurposeRadiomics has already been proposed as a prognostic biomarker in head and neck cancer (HNSCC). However, its predictive power in radiotherapy has not yet been studied. Here, we investigated a local radiomics approach to distinguish between tumor sub-volumes with different levels of radiosensitivity as a possible target for radiation dose intensification.Materials and MethodsOf 40 patients (n=28 training and n=12 validation) with biopsy confirmed locally recurrent HNSCC, pretreatment contrast-enhanced CT images were registered with follow-up PET/CT imaging allowing identification of controlled (GTVcontrol) vs non-controlled (GTVrec) tumor sub-volumes on pretreatment imaging. A bi-regional model was built using radiomic features extracted from pretreatment CT in the GTVrec and GTVcontrol to differentiate between those regions. Additionally, concept of local radiomics was implemented to perform detection task. The original tumor volume was divided into sub-volumes with no prior information on the location of recurrence. Radiomic features from those sub-volumes were then used to detect recurrent sub-volumes using multivariable logistic regression.ResultsRadiomic features extracted from non-controlled regions differed significantly from those in controlled regions (training AUC = 0.79 CI 95% 0.66 - 0.91 and validation AUC = 0.88 CI 95% 0.72 – 1.00). Local radiomics analysis allowed efficient detection of non-controlled sub-volumes both in the training AUC = 0.66 (CI 95% 0.56 – 0.75) and validation cohort 0.70 (CI 95% 0.53 – 0.86), however performance of this model was inferior to bi-regional model. Both models indicated that sub-volumes characterized by higher heterogeneity were linked to tumor recurrence.ConclusionLocal radiomics is able to detect sub-volumes with decreased radiosensitivity, associated with location of tumor recurrence in HNSCC in the pre-treatment CT imaging. This proof of concept study, indicates that local CT radiomics can be used as predictive biomarker in radiotherapy and potential target for dose intensification.

Highlights

  • Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 4% of all malignancies across Europe and the USA [1, 2]

  • Several early clinical trials have studied the role of radiation dose intensification to the primary tumor and metastatic lymph nodes in order to improve local control for HNSCC [5,6,7]

  • Heterogeneity within a tumor has been recognized as a characteristic of head and neck cancer [10], with some sub-regions being more resistant to radiochemotherapy

Read more

Summary

Introduction

Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 4% of all malignancies across Europe and the USA [1, 2]. Despite advances in treatment using modern radiotherapy delivery techniques, local recurrences still occur in up to 50% of patients and pose the predominant pattern of failure in HNSCC [3]. Several early clinical trials have studied the role of radiation dose intensification to the primary tumor and metastatic lymph nodes in order to improve local control for HNSCC [5,6,7]. The strategy of treatment intensification to these subvolumes could lead to better outcomes in terms of local control and subsequently overall survival, without a significant increase in treatment-related toxicities. Recent advancement in radiation technology in principle allows such an escalation of radiation dose to tumor sub-volumes. Identification of these subvolumes is a crucial step within this therapeutic concept

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call